Pfizer CEO Albert Bourla on Tuesday (Oct. 29) told investors that the company would be willing to pay a larger share of costs in Medicare Part D in exchange for a cap on beneficiaries’ out-of-pocket costs. He blamed increasing beneficiary cost-sharing for souring public sentiment on drug makers. “I would tell you that we are fanatically in favor of reducing out-of-pocket cost for patients. Because right now the fundamental issue that drives this polarization in the political environment around healthcare,...